Abstract
Cerebral sinovenous thrombosis (CSVT) is a rare but serious cerebrovascular disorder affecting children from the newborn period through childhood and adolescence. The incidence is estimated at 0.6/100,000/year, with 30–50% occurring in newborns. Causes are diverse and are highly age dependent. Acute systemic illness is the dominant risk factor among newborns. In childhood CSVT, acute infections of the head and neck such as mastoiditis are most common, followed by chronic underlying diseases such as nephrotic syndrome, cancer, and inflammatory bowel disease. Signs and symptoms are also age related. Seizures and altered mental status are the commonest manifestations in newborns. Headache, vomiting, and lethargy, sometimes with 6th nerve palsy, are the most common symptoms in children and adolescents. Recent multicenter cohort studies from North America and Europe have provided updated information on risk factors, clinical presentations, treatment practices, and outcomes. While systemic anticoagulation is the most common specific treatment used, there are wide variations and many uncertainties even among experts concerning best practice. The treatment dilemma is especially pronounced for neonatal CSVT. This is due in part to the higher prevalence of intracranial hemorrhage among newborns on the one hand, and the clear evidence that newborns suffer greater long-term neurologic morbidity on the other hand. With the advent of widespread availability and acceptance of acute endovascular therapy for arterial ischemic stroke, there is renewed interest in this therapy for children with CSVT. Limited published evidence exists regarding the benefits and risks of these invasive therapies. Therefore, the authors of current guidelines advise reserving this therapy for children with progressive and severe disease who have failed optimal medical management. As research focused on childhood cerebrovascular disease continues to grow rapidly, the future prospects for improving knowledge about this disorder should be good.
Highlights
The cerebral venous system is composed of a network of cortical, medullary, and deep veins which drain into dural venous sinuses
Thrombosis in the cerebral venous system impedes venous outflow, resulting in increased central venous pressure, which in turn causes intracranial hypertension. This leads to cerebral ischemia, which may evolve to infarction, often hemorrhagic
(6) Duration of AC treatment: 3–6 months is a reasonable duration of treatment for patients with provoked Cerebral sinovenous thrombosis (CSVT); 6–12 months for patients with spontaneous unprovoked CSVT in the absence of a strong permanent thrombophilia; lifelong for patients with a severe thrombophilia
Summary
Cerebral sinovenous thrombosis (CSVT) is a rare but serious cerebrovascular disorder affecting children from the newborn period through childhood and adolescence. The treatment dilemma is especially pronounced for neonatal CSVT This is due in part to the higher prevalence of intracranial hemorrhage among newborns on the one hand, and the clear evidence that newborns suffer greater long-term neurologic morbidity on the other hand. Thrombosis in the cerebral venous system impedes venous outflow, resulting in increased central venous pressure, which in turn causes intracranial hypertension In some cases, this leads to cerebral ischemia, which may evolve to infarction, often hemorrhagic. The long-term outcome of CSVT in children is variable and depends on the age of incident disease, comorbid diseases, and presence of acute complications (Table 2).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
